Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration

Abstract

Purpose  Real-world data give different information on health-care delivery compared with randomised controlled trials. We aimed to evaluate the appropriateness of possible quality standards for intersite comparisons of outcomes of providing Aflibercept for neovascular age-related macular degeneration (nAMD) in clinical practice.

Patients and methods  Retrospective data analysis from an electronic medical record. A consecutive series of treatment-naive patients initiated on Aflibercept for nAMD, in the UK from March 2013 to October 2015. Age, visual acuity (VA) at baseline and 1 year, and injection episodes were remotely extracted in an anonymised format.

Results  The mean baseline VA was 54.3 letters, ranging from 51.3 to 58.1 between different centres, in 5620 eyes taken from 12 centres. Out of these, 3360 were initiated on treatment more than a year before. The percentage with <35 letters at baseline was 19.9–3% and that with ≥70 letters was 24.8–10.7%. Eyes with ≥70 letters at 1 year ranged from 20.2 to 42.9% and those with <35 ranged from 4.5 to 21.6% across different sites. Injection rates in 1 year varied from 5.5 to 8.6, and data available at 1 year also varied from 82.3 to 46.4%.

Conclusions  Significant variation was found between sites attempting to provide the same therapeutic regime. For fair comparisons between sites, we recommend that both VA measures and process measures, such as injection numbers, retention rates, and discharge policies, are used. More work is required to explain the differences. Such real-world data are not generated in the same way as a randomised clinical trial, and maybe best used to help improve service provision.

Eye (2017) 31, 1613–1620; doi:10.1038/eye.2017.86; published online 23 June 2017

Introduction

Anti-vascular endothelial growth factor therapy has been shown to be effective in randomised controlled clinical trials (RCTs) and is the mainstay of treatment for neovascular age-related macular degeneration (nAMD).1–3 Increasingly, real-world data are being used to generate real-world evidence as a way of assessing the performance of a therapy in clinical practice.4–12 RCTs demonstrate the efficacy of an intervention, whereas real-world evidence explores its effectiveness—in other words, how it works in real-world conditions.13,14 A broader range of patients will be treated outside RCTs, and factors such as clinician’s decisions, service demands, and differences in assessment methods will influence the results. In ophthalmology, in addition to visual acuity (VA) measures, outcomes such as number of injections and patient compliance with treatment may have important service provision implications. Payers, service providers, and users are becoming more interested in such outcome measures.15 Therefore, there is a trend...
to set benchmarks or quality standards based on large real-world data sets.\(^4\)\(^{-12}\) However, for data to be used in this way, it is important to establish what outcome measures would be a fair reflection on the quality of a service and the minimum data sets required at each site to allow such comparisons.

In our previous paper, we confirmed that the mean VA improvement is inversely related to starting VA (the worse the baseline VA the greater the gain) and that second presenting eyes often have better baseline VA and maintain better VA than first eyes but have less mean improvement.\(^1\)\(^{11}\) We concluded that potentially useful quality standards could be based on the mean presenting VA as a measure of the quality of the referral to treatment pathway, and the percentage of treated eyes with 70 or more VA letters at annual time points as a measure of quality of the clinical care pathway within the service provision.\(^1\)\(^{11}\)

With real-world data, often VA is recorded with habitual correction rather than full correction, and certainly the recording of VA is not done as robustly as in a clinical trial, which is likely to underestimate the VA.\(^1\)\(^6\) Large data sets from the United Kingdom should provide a fairer measure of expected VA outcomes for real-life UK practice rather than RCT data. The objective of this study was, therefore, to provide such data and to evaluate a more comprehensive set of outcome measures across multiple sites in the United Kingdom to try and derive quality standards that may be used to evaluate service provision for nAMD and suggest sample sizes that could be used for a fair comparison. We explored whether there were any significant differences in baseline VA, age, number of injections given over a year, percentage of patients remaining under follow-up, and eyes with \(\geq 70\) letters at 1 year for treatment-naive patients. We also looked at factors that might influence these measures. For baseline and 1-year mean visual acuities, we looked at the proportion of patients with \(< 35\) letters and \(\geq 70\) letters at baseline and 1 year in keeping with our proposed quality standards in our previous publication. These standards reflect how patients presented in different centres and the quality of the clinical care pathway. The differences between sites may also represent differences in clinician practice in terms of criteria used to initiate, maintain, and stop treatment.

Data from 16 centres in the United Kingdom working in the same health system that used the same electronic medical record (EMR) to record all clinical data throughout the anti-VEGF care pathway were included. All centres planned to use only aflibercept to treat treatment-naive nAMD, with the intention of following the VIEW protocol.

This is not a RCT but a collection of data from several centres attempting to provide the same treatment in clinical practice. Such data are being used to evaluate service provision; therefore, it is important to explore whether there are significant differences between sites in terms of the proposed quality standards in order to ascertain whether these quality standards are generalisable to be used as fair measures of outcome in the real world.

**Materials and methods**

Data were collected to compare the mean baseline VA between sites; the proportion of eyes with \(< 35\) letters and \(\geq 70\) letters at baseline; the proportion of first to second affected eyes; the proportion of patients who had the potential to have data at 1 year who had data recorded; the mean number of injections given over 1 year and the proportion with VA \(\geq 70\) letters at 1 year.

Anonymised data were extracted from 16 United Kingdom National Health Service Hospitals, as detailed in the acknowledgements section, that confirmed they intended to use aflibercept on all treatment-naive eyes with nAMD following the VIEW protocol; three injections 1 month apart and then two monthly for the first year.\(^1\)\(^{1}\) The first treatment was initiated in March 2013 and data cutoff for this analysis was October 2015. All data were recorded using a single EMR system (Medisoft Ophthalmology, Medisoft Limited, Leeds, UK), which mandated collection of a standardised data set throughout the nAMD care pathway, which included VA, and injections given at each visit. The lead clinician and Caldicott Guardian (responsible nominee for data protection) at each NHS Hospital gave written approval for anonymised data extraction. Anonymised database analyses of this type do not require ethical permission as they are viewed as audit or service evaluation (see http://www.hra.nhs.uk/research-community/beforeyou-apply/determine-whether-your-study-is-research/). This study was conducted in accordance with the declaration of Helsinki and the UK Data Protection Act.

Although this study is retrospective in nature, the data set mandated by the EMR was defined prospectively before first data entry and hence the study methodology is somewhat closer to an electronic case report form used in clinical trials than a conventional analysis of unstructured data in a retrospective chart review.

**VA imputation**

ETDRS (Early treatment diabetic retinopathy study) VA letter scores were recorded at 2 m at each visit at all sites. At each visit, the best-measured VA value was used in analysis. Most VA values were recorded using habitual correction rather than with refraction. Values corresponding to count fingers, hand movements,
perception of light (PL) and no PL were substituted with values of 0 letters. In order to be able to plot VA at monthly time points and to maximise the sample size of eyes contributing to the data at each time point, a limited form of data interpolation was used such that a missing month(s) VA value was interpolated based on the mean of the VA letter score before and after the missing time point.

**Statistical methods**

Continuous normally distributed data were summarised using means, SEMs, and quartiles. Skewed continuous data were summarised using the medians and quartiles. Despite the skewness and kurtosis of the VA letter score data, the large sample sizes allowed parametric methods to be used for comparison of the means of groups. To enable this, and to include a site in the full analysis, the site had to have a sample size of 100 eyes contributing to the data at each time point, a limited form of data interpolation was used such that a missing month(s) VA value was interpolated based on the mean VA letter score before and after the missing time point.

**Results**

The 16 sites had recorded data on 5815 treatment-naive eyes receiving aflibercept for nAMD at the time of data cutoff. Four sites were excluded from further analysis because of low numbers expected to have reached 52 weeks due to delays in them starting using aflibercept for treatment-naive nAMD. The mean age of the patients was 80.0 years (median 81.0 years) and 63.5% were women. Data for comparison of VA at baseline were available on 2412 (71.8%) eyes from a possible 3360. The number of eyes varied per site from 177 to 1138.

Table 1 shows the mean baseline VA scores and SEs. The mean baseline VA between sites varied from 51.3 to 58.1 letters, with a median from 53 to 60 letters. For the mean, sites A and G had significantly higher scores, while sites D, F, and L had significantly lower scores.

With a sample size of 198 per site, we were able to detect with 80% statistical power a difference of four letters from a target value of 54, this being the mean VA. This assumes that Type I error is 5% (this is the probability that one can falsely conclude that any of 12 sites has baseline score significantly different from 54). With a sample size of 352, we can similarly detect a difference of three letters from the target value.

At baseline, 637 (11.3%) out of 5620 eyes had poor VA (≤35 letters; Table 2). The proportion with <35 letters varied by site, with significantly higher percentages of 17.5%, 19.9%, and 16.3%, respectively, for sites D, F, and L, and significantly lower percentages of 7.7% and 3.0%, respectively, for sites C and G.

In all, 985 (17.5%) out of the 5620 eyes had good VA (≥70 letters) at baseline. This proportion also varied by site with significantly higher percentages of 24.8% and 22.5%, respectively, for sites A and G and significantly lower percentages of 11.7%, 10.7%, and 13.2%, respectively, for sites D, F, and L.

In all, 1200 (21.4%) out of the 5620 eyes treated at baseline were second eyes. There was little variation by site and the differences were not statistically significant.

In all, 2412 (71.8%) out of 3360 eyes initiated on aflibercept 1 year or more from initial treatment were still being followed up at 1 year from baseline (Table 3). This proportion also varied by site, with significantly higher proportion of 82.3% and 78.2%, respectively, for sites A and G, and significantly lower percentages of 58.4% and 46.4%, respectively, for sites B and K.

The median number of injections recorded was 7 with an interquartile range of 3.

Sites D, F, and G gave a significantly higher number of injections of, respectively, 8.2, 8.6, and 8.1, while sites K and L gave a significantly lower numbers of injections of, respectively, 5.5 and 5.8.

With a sample size of 194 in a site we were able to detect with 80% statistical power a difference of 5% from a target value of 25% for having ≥70 letters at 1 year.

| Site | Eyes | Baseline; median Score; mean | P-value* |
|------|------|-----------------------------|----------|
| A    | 1138 | 20.3 59 (46, 69) 56.6 (0.5)   | <0.001*  |
| B    | 483  | 8.6 58 (45, 67) 55.3 (0.7)   | 0.151    |
| C    | 584  | 10.4 55 (45, 65) 53.8 (0.6)   | 0.404    |
| D    | 514  | 9.2 54 (40, 64) 52.0 (0.7)   | 0.001*   |
| F    | 271  | 4.8 55 (39, 65) 51.3 (1.0)   | 0.004*   |
| G    | 600  | 10.7 60 (50, 68) 58.1 (0.5)   | <0.001*  |
| H    | 329  | 5.9 55 (42, 65) 53.1 (0.9)   | 0.165    |
| K    | 397  | 7.1 54 (42, 65) 52.1 (0.8)   | 0.006    |
| L    | 698  | 12.4 53 (40, 65) 51.7 (0.6)   | <0.001*  |
| M    | 177  | 3.2 59 (41, 68) 53.5 (1.2)   | 0.514    |
| N    | 251  | 4.5 57 (44, 65) 54.1 (1.0)   | 0.844    |
| P    | 178  | 3.2 59 (42, 68) 55.2 (1.2)   | 0.467    |
| Total| 5620 | 100.0 57 (44, 66) 54.3 (0.2) |          |

E, I, J, and O sites were excluded because of having insignificantly numbers of patients expected at 1 year, see Materials and methods. *Significant after Bonferroni adjustment for multiple testing.
The 2412 eyes with letter scores at 52 weeks were analysed, and it was found that the percentage of eyes achieving ≥70 letters at 52 weeks varied between 20.2% for site N to 42.8% for site G, while overall the percentage was 33.4% (Table 4). The proportion of patients under follow-up with <35 letters at 1 year varied from 4.5 to 21.6%.

A logistic regression model was fitted to the data, and this showed that the prevalence of eyes achieving ≥70 letters at 52 weeks increases in proportion to the number of injections: an increase of one injection increases the odds of ≥70 letters by 4% (odds ratio is 1.04 with 95% CI 1.01–1.08; Table 5). The prevalence of this outcome decreases with age: those aged 70–79, 80–84, and 85+ have reduced prevalence with odds ratios of 0.68, 0.49, and 0.37, respectively. This prevalence also increases with baseline VA letter scores. Relative to subjects with letter scores of 50–59 at baseline, a baseline score of under 45 letters decreases the odds of ≥70 VA letter score by 76% (odds ratio of 0.24 with 95% CI 0.17–0.34). Conversely, a baseline score of 60–64 increases the odds by 57% (odds ratio is 1.47 with 95% CI 1.16–2.13). Attending site G increased the odds by 53% (odds ratio with 95% CI 1.15–2.05). Possible interactions between age and number of injections were tested for and found not to be significant.

**Discussion**

In our previous publication on 1840 treatment-naive eyes on aflibercept therapy for nAMD, we found that the amount of VA gain depended on the presenting VA and on whether a first or second affected eye was being treated as second affected eyes are often initiated on aflibercept service provision. In our previous publication on 1840 treatment-naive eyes on aflibercept therapy for nAMD, we found that the amount of VA gain depended on the presenting VA and on whether a first or second affected eye was being treated as second affected eyes are often initiated on aflibercept service provision.

This assumes that Type I error is 5% (this is the probability that one can falsely conclude that any of 12 sites has percentage different from 25). With a sample size of 302, we can similarly detect a difference of 4% from the target value.

The 2412 eyes with letter scores at 52 weeks were analysed, and it was found that the percentage of eyes achieving ≥70 letters at 52 weeks varied between 20.2% for site N to 42.8% for site G, while overall the percentage was 33.4% (Table 4). The proportion of patients under follow-up with <35 letters at 1 year varied from 4.5 to 21.6%.

A logistic regression model was fitted to the data, and this showed that the prevalence of eyes achieving ≥70 letters at 52 weeks increases in proportion to the number of injections: an increase of one injection increases the odds of ≥70 letters by 4% (odds ratio is 1.04 with 95% CI 1.01–1.08; Table 5). The prevalence of this outcome decreases with age: those aged 70–79, 80–84, and 85+ have reduced prevalence with odds ratios of 0.68, 0.49, and 0.37, respectively. This prevalence also increases with baseline VA letter scores. Relative to subjects with letter scores of 50–59 at baseline, a baseline score of under 45 letters decreases the odds of ≥70 VA letter score by 76% (odds ratio of 0.24 with 95% CI 0.17–0.34). Conversely, a baseline score of 60–64 increases the odds by 57% (odds ratio is 1.47 with 95% CI 1.16–2.13). Attending site G increased the odds by 53% (odds ratio with 95% CI 1.15–2.05). Possible interactions between age and number of injections were tested for and found not to be significant.

**Discussion**

In our previous publication on 1840 treatment-naive eyes on aflibercept therapy for nAMD, we found that the amount of VA gain depended on the presenting VA and on whether a first or second affected eye was being treated as second affected eyes are often initiated on aflibercept service provision.

This assumes that Type I error is 5% (this is the probability that one can falsely conclude that any of 12 sites has percentage different from 25). With a sample size of 302, we can similarly detect a difference of 4% from the target value.

The 2412 eyes with letter scores at 52 weeks were analysed, and it was found that the percentage of eyes achieving ≥70 letters at 52 weeks varied between 20.2% for site N to 42.8% for site G, while overall the percentage was 33.4% (Table 4). The proportion of patients under follow-up with <35 letters at 1 year varied from 4.5 to 21.6%.

A logistic regression model was fitted to the data, and this showed that the prevalence of eyes achieving ≥70 letters at 52 weeks increases in proportion to the number of injections: an increase of one injection increases the
Table 4  Eyes with ≤35 and ≥70 VA letter score at 52 weeks by site

| Site | total | N | Percent with 95% CI | P-value* |
|------|-------|---|---------------------|---------|
| A    | 613   | 55 | 9.0 (5.7, 12.3)     | 0.015   |
| B    | 139   | 10 | 7.2 (0.9, 13.5)     | 0.037   |
| C    | 241   | 28 | 11.6 (5.7, 17.5)    | 0.940   |
| D    | 223   | 42 | 18.8 (11.3, 26.3)   | 0.007   |
| F    | 115   | 20 | 17.4 (7.3, 27.5)    | 0.112   |
| G    | 290   | 13 | 4.5 (1.0, 8.0)      | <0.001b|
| H    | 115   | 15 | 13.0 (4.0, 22.0)    | 0.686   |
| K    | 134   | 21 | 15.7 (6.7, 24.7)    | 0.215   |
| L    | 299   | 43 | 14.4 (8.6, 20.2)    | 0.199   |
| M    | 74    | 16 | 21.6 (7.9, 35.3)    | 0.040   |
| N    | 94    | 13 | 13.8 (3.6, 24.0)    | 0.564   |
| P    | 75    | 8  | 10.7 (0.5, 20.9)    | 0.756   |
| Total| 2412  | 284| 11.8 (9.9, 13.7)    |         |

Table 5 Influence of factors on VA letter score of 70 letters or more at 52 weeks

| Factor                                | Odds ratio | P-value |
|---------------------------------------|------------|---------|
| Number of injections                  | 1.04 (1.01, 1.08) | 0.007   |
| Age at baseline⁶                       | 0.68 (0.49, 0.93) | 0.018   |
| ≥70-79                                | 0.49 (0.35, 0.69) | <0.001  |
| 85 and over                           | 0.37 (0.26, 0.52) | <0.001  |
| Baseline visual acuity letters⁵       |             |         |
| Under 45                              | 0.24 (0.17, 0.35) | <0.001  |
| 45-49                                 | 0.46 (0.31, 0.71) | <0.001  |
| 60-64                                 | 1.57 (1.16, 2.13) | <0.001  |
| 65-69                                 | 3.32 (2.47, 4.47) | <0.001  |
| 70-74                                 | 5.65 (4.08, 7.83) | <0.001  |
| 75+                                   | 10.52 (6.75, 16.39) | <0.001  |
| Site G                                 | 1.53 (1.15, 2.05) | <0.001  |

*P-value for comparison with percentage for all sites. ⁶Significant after Bonferroni adjustment for multiple testing.

consecutive patients’ data at a site is required to make meaningful intersite comparisons. This study showed that with a sample size of 198 in a site we were able to detect with 80% statistical power a difference of four letters from a proposed target value of baseline VA of 54 letters, and with a sample size of 194 we were able to detect with 80% statistical power a difference of 5% from a target value of baseline VA of 54 letters, and by attending site G. In this study, sites had intended to follow the VIEW protocol, but there was a difference in the mean numbers of injections given. Fewer
injections are frequently associated with worse VA outcomes in many studies. Assessing a service on this parameter alone is insufficient as the number of injections given at a site depend on multiple factors, for example, the ability of the health-care service to provide the appropriate appointment intervals, patient attendance, and success, but also the futility criteria used at each site and whether such patients are followed up while not being treated or discharged. This is clearly illustrated with the proportion of patients with <35 letters still under follow-up at 1 year as that varied from 4.5 to 21.6%.

Other confounding factors that determine the outcome measures highlighted in this study include the highly significant differences in the proportions of patients with data at 1 year that varied from 46.4 to 82.3%. This proportion may not mean that the patients are no longer being treated. Patients may move to hospitals especially in larger cities. Therefore, failing to maintain this quality standard may not always reflect the inability of sites to provide timely appointments. Further scrutiny into local factors has to be investigated before assumptions are made on the quality of the service based on this quality standard.

A particular area of concern of benchmarking services based on the set quality standards is that there are several areas in the service provision in nAMD that lack evidence. For example, the clinical benefit and cost effectiveness of initiating treatment in eyes with very poor baseline VA, or maintaining treatment if little improvement is achieved in the first few months, particularly if VA in the fellow eye is good, has not been adequately studied. In cash-limited publicly funded health-care systems such evidence and guidance would be useful as clinicians negotiate with health-care purchasers. Other measures of benefit from treatment would involve quality of life measures such as recommended by the International Consortium for health-care outcomes, macular degeneration data collection guide (www.ichom.org/medical-conditions/macular-degeneration/). These are certainly to be recommended, but in practice can be difficult to carry out in busy clinical practice.

A report on intercentre variation in the United Kingdom from an older data set looking at the PRN use of ranibizumab for AMD also reported variations in service provision. It might be expected that our intersite comparisons would show more similarities between centres as there is now more experience with the use of anti-VEGF in centres and we were all attempting to provide the same regime of fixed dosing resulting in less variations. The study showed that a younger age, better starting VA, and a higher number of injections were associated with better VA outcomes, but we found that significant variation between centres persisted even after adjusting for these factors. We have highlighted other reasons for these differences.

In conclusion, we have proposed a number of outcomes and sample sizes that could be used together to evaluate the quality of a service. It is apparent that, while the differences we found could represent differences in the quality of care of patients they could also reflect differences in population characteristics as well as difficulties in recording standardised comparable VA measures and differences in a clinical approach, such as being more or less willing to start patients on therapy with lower VA levels and continuing patients under follow-up with lower VA. Differences in retention of patients under follow-up, or at least recording the data on the EMR used, may also be a factor. Other comparator measures could be non-VA based such as the incidence of new patients being treated; time to first treatment and number of visits. Further work is required to define and evaluate a set of appropriate measures to assess quality of care using anti-VEGF in nAMD. However, we recommend that both VA and process review should be evaluated while assessing anti-VEGF clinical care pathways for neovascular AMD. As a minimum we recommend the following to be reported while auditing services: (1) proportion of patients with presenting VA <35 and ≥70 letters, (2) proportion of patients with VA <35 and ≥70 letters at 1 year, (3) number of injections in 1 year, and (4) rate of retention of patients at 1 year. More work will need to be done to recommend the minimum achievable standards. In addition, further analysis of real-world outcomes over multiple years of follow-up will provide us with the information required for on-going yearly service evaluation.

Summary

What was known before
- Real-world evidence of outcomes is not the same as for randomised controlled trials. VA results from anti-VEGF therapy are not usually as good from real-world data compared with randomised clinical trials.

What this study adds
- There are significant differences in outcome data between sites attempting to provide the same therapy that may or may not relate to the quality of the service. For fair comparisons between sites we recommend that both VA measures and process measures, such as injection numbers, retention rates, and discharge policies are used. Real-world data may help provide evidence to improve the quality of services.

Conflict of interest
RLJ was the Medical Director of Medisoft Limited and the Electronic Medical Record Supplier to all the sites contributing to this study. The remaining authors declare no conflict of interest.
Acknowledgements

Medisoft and Newcastle Upon Tyne Hospitals NHS Foundation Trust received support for data extraction and analysis from Bayer. The authors have received travel bursaries and attended advisory boards for Bayer, Novartis, and Allergan.

Disclaimer

Bayer was not involved in the data collection, analysis, or writing of this paper.

UK Afiberecept Users Group

AJ Lotery7, F Ghanchi8, N Patel9, C Bailey10, S Mahmood11, A Lobo12, B Paul13, Q Kashif14, C Santiago15, G Walters16, M Tahir17, B Mushtaq18, K Ahmed19, M McKibbin20, S Sivaprasad21, J Talks22

7University of Southampton, Southampton; 8Bradford Teaching Hospitals, Bradford, UK; 9East Kent Hospitals University NHS Foundation Trust, Canterbury, UK; 10University Hospitals Bristol NHS Foundation Trust, Bristol, UK; 11Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK; 12Moorfields Eye Unit, Bedford Hospital NHS Trust, Bedford, UK; 13Barking, Havering and Redbridge University Hospitals NHS Trust, London, UK; 14East Sussex Hospitals NHS Trust, Sussex, UK; 15Grampian NHS, Aberdeen, UK; 16Harrowgate Hospital, Harrogate, UK; 17Berkshire NHS Trust, Berkshire, UK; 18Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK; 19Aintree NHS Trust, Liverpool, UK; 20Leeds Teaching Hospitals NHS Trust, Leeds, UK; 21Kings College Hospital NHS Foundation Trust and Moorfields Eye Hospital, London, UK; 22Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

References

1 Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537–2548.
2 Brown DM, Kaiser PK, Michels M, Soubzane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444.
3 Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
4 Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014; 121: 1092–1101.
5 Pushpoth S, Sykakis E, Merchant K, Browning AC, Gupta R, Talks SJ. Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96: 1469–1473.
6 Pagliarini S, Beatty S, Lipkova B, Perez-Salvador Garcia E, Reynders S, Gekkieva M et al. A 2-year, phase iv, multicentre, observational study of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration in routine clinical practice: The EPICOHORT Study, J Ophthalmol 2014; 2014: 857148.
7 Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) 2016; 30: 270–286.
8 Gillies MC, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology 2014; 121: 676–681.
9 Arnold JJ, Campion A, Barathelms D, Simpson JM, Guymer RH, Hunyor AP et al. Two-year outcomes of ‘Treat and Extend,’ intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology 2015; 122: 1212–1219.
10 Freund BK, Korobelnik JF, Devenyi R, Framme C, Talks J, Wolff S et al. Treat and extend regimes with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina 2015; 35: 1489–1506.
11 Talks SJ, Lotery AJ, Ghanchi F, Sivaprasad S, Johnston RL, Patel N et al. UK first-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration. Ophthalmology 2016; 123: 337–343.
12 Holtz F, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015; 99: 220–226.
13 Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol 2014; 5: e45.
14 Rothwell PM. External validity of randomized controlled trials: ‘to whom do the results of this trial apply?’ Lancet 2005; 365(9453): 82–93.
15 Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL et al. Real-world evidence- what is it and what can it tell us? N Engl J Med 2016; 375(23): 2293–2297.
16 Gilles MC, Nguyen V, Daen V, Arnold JJ, Morlet N, Barthelems D. Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology 2016; 123(12): 2545–2553.
17 Arias L, Armada F, Donate J, Garcia-Arumi J, Giralt J, Pazos B et al. Delay in treating age-related macular degeneration in Spain is associated with progressive visual loss. Eye 2009; 23: 326–333.
18 Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD et al. Delay to treatment and visual acuity outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012; 153: 678–686.
19 Regillo CD, Brown DM, Abraham P, PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. *Am J Ophthalmol* 2008; 145: 239–248.

20 Rodrigues IA, Sprinkhuizen SM, Barthelmes D, Blumenkranz M, Cheung G, Haller J et al. Defining a minimum set of standardized patient-centered outcome measures for macular degeneration. *Am J Ophthalmol* 2016; 168: 1–12.

21 Liew G, Lee AY, Zarranz-Ventura J, Stratton I, Bunce C, Chakravarthy U et al. The UK Neovascular AMD database report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. *Eye (Lond)* 2016; 30(11):1462–1468.